|
gptkbp:instanceOf
|
gptkb:brand
gptkb:drug
|
|
gptkbp:activeIngredient
|
conjugated estrogens
|
|
gptkbp:approvedBy
|
gptkb:FDA
1942
|
|
gptkbp:ATCCode
|
G03CA57
|
|
gptkbp:chemicalClass
|
estrogen
|
|
gptkbp:contains
|
gptkb:17α-dihydroequilenin_sulfate
gptkb:17β-dihydroequilenin_sulfate
gptkb:17β-dihydroequilin_sulfate
gptkb:equilenin_sulfate
gptkb:equilin
estradiol sulfate
estrone
estrone sulfate
17α-dihydroequilin sulfate
equilin sulfate
|
|
gptkbp:contraindication
|
gptkb:cancer
liver dysfunction
active thromboembolic disorder
undiagnosed vaginal bleeding
|
|
gptkbp:derivedFrom
|
pregnant mare urine
|
|
gptkbp:form
|
gptkb:butter
gptkb:tablet
injectable
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Premarin
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Pfizer
|
|
gptkbp:marketedIn
|
gptkb:Australia
gptkb:Canada
gptkb:Europe
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:pregnancyCategory
|
X
|
|
gptkbp:routeOfAdministration
|
oral
topical
intravenous
|
|
gptkbp:sideEffect
|
nausea
headache
breast tenderness
increased risk of blood clots
increased risk of stroke
increased risk of endometrial cancer
vaginal bleeding
|
|
gptkbp:usedFor
|
gptkb:cancer
prostate cancer
hypoestrogenism
menopausal symptoms
vaginal atrophy
osteoporosis prevention
vulvar atrophy
|
|
gptkbp:bfsParent
|
gptkb:Wyeth
|
|
gptkbp:bfsLayer
|
5
|